Research ExplorerPublicationsPopulation-based study of autoimmune hepatitis and primary b...

Population-based study of autoimmune hepatitis and primary biliary cholangitis in Germany: rising prevalences based on ICD codes, yet deficits in medical treatment

Standard

Population-based study of autoimmune hepatitis and primary biliary cholangitis in Germany: rising prevalences based on ICD codes, yet deficits in medical treatment. / Sebode, Marcial; Kloppenburg, Angela; Aigner, Annette; Lohse, Ansgar W; Schramm, Christoph; Linder, Roland.

In: Z GASTROENTEROL, Vol. 58, No. 5, 05.2020, p. 431-438.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Sebode, M, Kloppenburg, A, Aigner, A, Lohse, AW, Schramm, C & Linder, R 2020, 'Population-based study of autoimmune hepatitis and primary biliary cholangitis in Germany: rising prevalences based on ICD codes, yet deficits in medical treatment', Z GASTROENTEROL, vol. 58, no. 5, pp. 431-438. https://doi.org/10.1055/a-1135-9306

APA

Sebode, M., Kloppenburg, A., Aigner, A., Lohse, A. W., Schramm, C., & Linder, R. (2020). Population-based study of autoimmune hepatitis and primary biliary cholangitis in Germany: rising prevalences based on ICD codes, yet deficits in medical treatment. Z GASTROENTEROL, 58(5), 431-438. https://doi.org/10.1055/a-1135-9306

Vancouver

Sebode M, Kloppenburg A, Aigner A, Lohse AW, Schramm C, Linder R. Population-based study of autoimmune hepatitis and primary biliary cholangitis in Germany: rising prevalences based on ICD codes, yet deficits in medical treatment. Z GASTROENTEROL. 2020 May;58(5):431-438. https://doi.org/10.1055/a-1135-9306

Bibtex

@article{76d32900f93f4034881c0e001db7fac3,
title = "Population-based study of autoimmune hepatitis and primary biliary cholangitis in Germany: rising prevalences based on ICD codes, yet deficits in medical treatment",
abstract = "BACKGROUND:  Population-based data on the prevalence of and real-life treatment for the autoimmune liver diseases (AILD), primary biliary cholangitis (PBC) and autoimmune hepatitis (AIH), are scarce, and such knowledge may help to improve patient care.METHODS:  Data of 8.1 million individuals having health insurance with the {"}Techniker Krankenkasse,{"} the largest German health insurer, were analyzed with regard to the prevalence of and prescribed medication for AILD in Germany from 2011 until 2014. Patients with viral hepatitis B infection (HBV) and alcoholic liver cirrhosis (ALC) served as control groups. Case definition was based on ICD codes.RESULTS:  The prevalences of PBC and AIH were 36.9/100 000 inhabitants (95 % CI: 35.6-38.2) and 23.0/100 000 inhabitants (95 % CI: 22.0-24.0) in 2014, respectively. The prevalences of AILD increased from 2011 to 2014 (for PBC by 31 % and for AIH by 29 %), with the largest increase for male patients with PBC. In contrast, the prevalence of HBV declined while that of ALC remained stable. The analysis of prescribed real-life treatment revealed considerable deviations from standard treatment recommendations. Specifically, in older patients with PBC or AIH, undertreatment was common.CONCLUSION:  The prevalence of PBC and AIH based on ICD codes is increasing in Germany. The analysis of real-life treatment in this large and population-based cohort points to the unmet need to improve the implementation of treatment guidelines for autoimmune liver diseases in the broader medical community.",
keywords = "Aged, Germany/epidemiology, Hepatitis, Autoimmune/epidemiology, Humans, International Classification of Diseases, Liver Cirrhosis, Biliary/epidemiology, Male, Population Surveillance, Prevalence",
author = "Marcial Sebode and Angela Kloppenburg and Annette Aigner and Lohse, {Ansgar W} and Christoph Schramm and Roland Linder",
note = "{\textcopyright} Georg Thieme Verlag KG Stuttgart · New York.",
year = "2020",
month = may,
doi = "10.1055/a-1135-9306",
language = "English",
volume = "58",
pages = "431--438",
journal = "Z GASTROENTEROL",
issn = "0044-2771",
publisher = "Karl Demeter Verlag GmbH",
number = "5",

}

RIS

TY - JOUR

T1 - Population-based study of autoimmune hepatitis and primary biliary cholangitis in Germany: rising prevalences based on ICD codes, yet deficits in medical treatment

AU - Sebode, Marcial

AU - Kloppenburg, Angela

AU - Aigner, Annette

AU - Lohse, Ansgar W

AU - Schramm, Christoph

AU - Linder, Roland

N1 - © Georg Thieme Verlag KG Stuttgart · New York.

PY - 2020/5

Y1 - 2020/5

N2 - BACKGROUND:  Population-based data on the prevalence of and real-life treatment for the autoimmune liver diseases (AILD), primary biliary cholangitis (PBC) and autoimmune hepatitis (AIH), are scarce, and such knowledge may help to improve patient care.METHODS:  Data of 8.1 million individuals having health insurance with the "Techniker Krankenkasse," the largest German health insurer, were analyzed with regard to the prevalence of and prescribed medication for AILD in Germany from 2011 until 2014. Patients with viral hepatitis B infection (HBV) and alcoholic liver cirrhosis (ALC) served as control groups. Case definition was based on ICD codes.RESULTS:  The prevalences of PBC and AIH were 36.9/100 000 inhabitants (95 % CI: 35.6-38.2) and 23.0/100 000 inhabitants (95 % CI: 22.0-24.0) in 2014, respectively. The prevalences of AILD increased from 2011 to 2014 (for PBC by 31 % and for AIH by 29 %), with the largest increase for male patients with PBC. In contrast, the prevalence of HBV declined while that of ALC remained stable. The analysis of prescribed real-life treatment revealed considerable deviations from standard treatment recommendations. Specifically, in older patients with PBC or AIH, undertreatment was common.CONCLUSION:  The prevalence of PBC and AIH based on ICD codes is increasing in Germany. The analysis of real-life treatment in this large and population-based cohort points to the unmet need to improve the implementation of treatment guidelines for autoimmune liver diseases in the broader medical community.

AB - BACKGROUND:  Population-based data on the prevalence of and real-life treatment for the autoimmune liver diseases (AILD), primary biliary cholangitis (PBC) and autoimmune hepatitis (AIH), are scarce, and such knowledge may help to improve patient care.METHODS:  Data of 8.1 million individuals having health insurance with the "Techniker Krankenkasse," the largest German health insurer, were analyzed with regard to the prevalence of and prescribed medication for AILD in Germany from 2011 until 2014. Patients with viral hepatitis B infection (HBV) and alcoholic liver cirrhosis (ALC) served as control groups. Case definition was based on ICD codes.RESULTS:  The prevalences of PBC and AIH were 36.9/100 000 inhabitants (95 % CI: 35.6-38.2) and 23.0/100 000 inhabitants (95 % CI: 22.0-24.0) in 2014, respectively. The prevalences of AILD increased from 2011 to 2014 (for PBC by 31 % and for AIH by 29 %), with the largest increase for male patients with PBC. In contrast, the prevalence of HBV declined while that of ALC remained stable. The analysis of prescribed real-life treatment revealed considerable deviations from standard treatment recommendations. Specifically, in older patients with PBC or AIH, undertreatment was common.CONCLUSION:  The prevalence of PBC and AIH based on ICD codes is increasing in Germany. The analysis of real-life treatment in this large and population-based cohort points to the unmet need to improve the implementation of treatment guidelines for autoimmune liver diseases in the broader medical community.

KW - Aged

KW - Germany/epidemiology

KW - Hepatitis, Autoimmune/epidemiology

KW - Humans

KW - International Classification of Diseases

KW - Liver Cirrhosis, Biliary/epidemiology

KW - Male

KW - Population Surveillance

KW - Prevalence

U2 - 10.1055/a-1135-9306

DO - 10.1055/a-1135-9306

M3 - SCORING: Journal article

C2 - 32392605

VL - 58

SP - 431

EP - 438

JO - Z GASTROENTEROL

JF - Z GASTROENTEROL

SN - 0044-2771

IS - 5

ER -